We are the next generation of gene therapies
There’s a new frontier in the fight against devastating rare and prevalent diseases, and Affinia Therapeutics is pioneering the way. We’re expanding what’s possible with adeno-associated virus (AAV) gene therapy, starting with diseases of the heart and of the nervous system.
We call it ART and its breakthrough science
With our proprietary ART (Affinia Rationally-designed Therapies) platform, we employ AI and structural modeling to rationally design the gene therapies of tomorrow – ones that better target tissues and so, may improve safety and effectiveness.
We see what’s possible tomorrow by creating it today
There’s a new frontier in the fight against devastating rare and prevalent diseases, and Affinia Therapeutics is leading the way. We’re expanding what’s possible in adeno‑associated virus (AAV) gene therapy today to bring transformative medicines for people in need tomorrow.
Developing therapies
with breakthrough
rational design science
With our proprietary ART: Affinia Rationally-designed Therapies platform we generate a deep understanding of how structure impacts function to rationally design the gene therapies of tomorrow.